Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
Identifieur interne : 000D85 ( Main/Corpus ); précédent : 000D84; suivant : 000D86Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
Auteurs : Berta Luzn-Toro ; Elena Rubio De La Torre ; Asuncin Delgado ; Jordi Prez-Tur ; Sabine HilfikerSource :
- Human Molecular Genetics [ 0964-6906 ] ; 2007-09-01.
Abstract
Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.
Url:
DOI: 10.1093/hmg/ddm151
Links to Exploration step
ISTEX:5285C50C5E85B65CB52977E9337CFD2862CC522ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title><author><name sortKey="Luzn Toro, Berta" sort="Luzn Toro, Berta" uniqKey="Luzn Toro B" first="Berta" last="Luzn-Toro">Berta Luzn-Toro</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="De La Torre, Elena Rubio" sort="De La Torre, Elena Rubio" uniqKey="De La Torre E" first="Elena Rubio" last="De La Torre">Elena Rubio De La Torre</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="Delgado, Asuncin" sort="Delgado, Asuncin" uniqKey="Delgado A" first="Asuncin" last="Delgado">Asuncin Delgado</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="Prez Tur, Jordi" sort="Prez Tur, Jordi" uniqKey="Prez Tur J" first="Jordi" last="Prez-Tur">Jordi Prez-Tur</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Hilfiker, Sabine" sort="Hilfiker, Sabine" uniqKey="Hilfiker S" first="Sabine" last="Hilfiker">Sabine Hilfiker</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sabine.hilfiker@ipb.csic.es</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5285C50C5E85B65CB52977E9337CFD2862CC522E</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1093/hmg/ddm151</idno><idno type="url">https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title><author><name sortKey="Luzn Toro, Berta" sort="Luzn Toro, Berta" uniqKey="Luzn Toro B" first="Berta" last="Luzn-Toro">Berta Luzn-Toro</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="De La Torre, Elena Rubio" sort="De La Torre, Elena Rubio" uniqKey="De La Torre E" first="Elena Rubio" last="De La Torre">Elena Rubio De La Torre</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="Delgado, Asuncin" sort="Delgado, Asuncin" uniqKey="Delgado A" first="Asuncin" last="Delgado">Asuncin Delgado</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation></author><author><name sortKey="Prez Tur, Jordi" sort="Prez Tur, Jordi" uniqKey="Prez Tur J" first="Jordi" last="Prez-Tur">Jordi Prez-Tur</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Hilfiker, Sabine" sort="Hilfiker, Sabine" uniqKey="Hilfiker S" first="Sabine" last="Hilfiker">Sabine Hilfiker</name><affiliation><mods:affiliation>8100 Granada, Spain and</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sabine.hilfiker@ipb.csic.es</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Human Molecular Genetics</title><idno type="ISSN">0964-6906</idno><idno type="eISSN">1460-2083</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2007-09-01">2007-09-01</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">17</biblScope><biblScope unit="page" from="2031">2031</biblScope><biblScope unit="page" to="2039">2039</biblScope></imprint><idno type="ISSN">0964-6906</idno></series><idno type="istex">5285C50C5E85B65CB52977E9337CFD2862CC522E</idno><idno type="DOI">10.1093/hmg/ddm151</idno><idno type="ArticleID">ddm151</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0964-6906</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Berta Luzn-Toro</name><affiliations><json:string>Institute of Parasitology and Biomedicine Lpez-Neyra, Spanish National Research Council (CSIC), 18100 Granada, Spain and</json:string></affiliations></json:item><json:item><name>Elena Rubio de la Torre</name><affiliations><json:string>Institute of Parasitology and Biomedicine Lpez-Neyra, Spanish National Research Council (CSIC), 18100 Granada, Spain and</json:string></affiliations></json:item><json:item><name>Asuncin Delgado</name><affiliations><json:string>Institute of Parasitology and Biomedicine Lpez-Neyra, Spanish National Research Council (CSIC), 18100 Granada, Spain and</json:string></affiliations></json:item><json:item><name>Jordi Prez-Tur</name><affiliations><json:string>Institute of Biomedicine, Spanish National Research Council (CSIC), 46010 Valencia, Spain</json:string></affiliations></json:item><json:item><name>Sabine Hilfiker</name><affiliations><json:string>Institute of Parasitology and Biomedicine Lpez-Neyra, Spanish National Research Council (CSIC), 18100 Granada, Spain and</json:string><json:string>E-mail: sabine.hilfiker@ipb.csic.es</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>ARTICLES</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.</abstract><qualityIndicators><score>6.548</score><pdfVersion>1.2</pdfVersion><pdfPageSize>609.675 x 795.005 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>937</abstractCharCount><pdfWordCount>6474</pdfWordCount><pdfCharCount>41234</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>129</abstractWordCount></qualityIndicators><title>Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title><genre><json:string>research-article</json:string></genre><host><volume>16</volume><pages><last>2039</last><first>2031</first></pages><issn><json:string>0964-6906</json:string></issn><issue>17</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2083</json:string></eissn><title>Human Molecular Genetics</title></host><categories><wos><json:string>BIOCHEMISTRY & MOLECULAR BIOLOGY</json:string><json:string>GENETICS & HEREDITY</json:string></wos></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1093/hmg/ddm151</json:string></doi><id>5285C50C5E85B65CB52977E9337CFD2862CC522E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>OUP</p></availability><date>2007-06-20</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title><author><persName><forename type="first">Berta</forename><surname>Luzn-Toro</surname></persName><affiliation>8100 Granada, Spain and</affiliation></author><author><persName><forename type="first">Elena Rubio</forename><surname>de la Torre</surname></persName><affiliation>8100 Granada, Spain and</affiliation></author><author><persName><forename type="first">Asuncin</forename><surname>Delgado</surname></persName><affiliation>8100 Granada, Spain and</affiliation></author><author><persName><forename type="first">Jordi</forename><surname>Prez-Tur</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">Sabine</forename><surname>Hilfiker</surname></persName><email>sabine.hilfiker@ipb.csic.es</email><affiliation>8100 Granada, Spain and</affiliation></author></analytic><monogr><title level="j">Human Molecular Genetics</title><idno type="pISSN">0964-6906</idno><idno type="eISSN">1460-2083</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2007-09-01"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">17</biblScope><biblScope unit="page" from="2031">2031</biblScope><biblScope unit="page" to="2039">2039</biblScope></imprint></monogr><idno type="istex">5285C50C5E85B65CB52977E9337CFD2862CC522E</idno><idno type="DOI">10.1093/hmg/ddm151</idno><idno type="ArticleID">ddm151</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007-06-20</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>ARTICLES</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-06-20">Created</change><change when="2007-09-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-15">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">hmg</journal-id><journal-id journal-id-type="hwp">hmg</journal-id><journal-title>Human Molecular Genetics</journal-title><issn pub-type="ppub">0964-6906</issn><issn pub-type="epub">1460-2083</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/hmg/ddm151</article-id><article-id pub-id-type="publisher-id">ddm151</article-id><article-categories><subj-group><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luzón-Toro</surname><given-names>Berta</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>de la Torre</surname><given-names>Elena Rubio</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Delgado</surname><given-names>Asunción</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pérez-Tur</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hilfiker</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Institute of Parasitology and Biomedicine ‘López-Neyra’</addr-line>, <institution>Spanish National Research Council (CSIC)</institution>, <addr-line>18100 Granada</addr-line>, <country>Spain</country> and</aff><aff id="af2"><label>2</label><addr-line>Institute of Biomedicine</addr-line>, <institution>Spanish National Research Council (CSIC)</institution>, <addr-line>46010 Valencia</addr-line>, <country>Spain</country></aff><author-notes><corresp id="cor1"><label>*</label>To whom correspondence should be addressed at: <addr-line>Parque Tecnológico de Ciencias de la Salud, Avda del Conocimiento s/n, 18100 Granada</addr-line>, <country>Spain</country>. Tel: <phone>+34 958181654</phone>; Fax: <fax>+34 958181632</fax>; Email: <email>sabine.hilfiker@ipb.csic.es</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2007</year></pub-date><volume>16</volume><issue>17</issue><fpage>2031</fpage><lpage>2039</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2007</year></date></history><copyright-statement>© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2007</copyright-year><abstract><p>Pathogenic mutations in the leucine-rich repeat kinase-2 (<italic>LRRK2</italic>) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation</title></titleInfo><name type="personal"><namePart type="given">Berta</namePart><namePart type="family">Luzn-Toro</namePart><affiliation>8100 Granada, Spain and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elena Rubio</namePart><namePart type="family">de la Torre</namePart><affiliation>8100 Granada, Spain and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Asuncin</namePart><namePart type="family">Delgado</namePart><affiliation>8100 Granada, Spain and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jordi</namePart><namePart type="family">Prez-Tur</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sabine</namePart><namePart type="family">Hilfiker</namePart><affiliation>8100 Granada, Spain and</affiliation><affiliation>E-mail: sabine.hilfiker@ipb.csic.es</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>ARTICLES</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2007-09-01</dateIssued><dateCreated encoding="w3cdtf">2007-06-20</dateCreated><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.</abstract><relatedItem type="host"><titleInfo><title>Human Molecular Genetics</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0964-6906</identifier><identifier type="eISSN">1460-2083</identifier><identifier type="PublisherID">hmg</identifier><identifier type="PublisherID-hwp">hmg</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>17</number></detail><extent unit="pages"><start>2031</start><end>2039</end></extent></part></relatedItem><identifier type="istex">5285C50C5E85B65CB52977E9337CFD2862CC522E</identifier><identifier type="DOI">10.1093/hmg/ddm151</identifier><identifier type="ArticleID">ddm151</identifier><accessCondition type="use and reproduction" contentType="copyright">The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissionsoxfordjournals.org</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>text/html</mimetype><extension>html</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/covers/html</uri></json:item><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/covers/tiff</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/annexes/gif</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/5285C50C5E85B65CB52977E9337CFD2862CC522E/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">BIOCHEMISTRY & MOLECULAR BIOLOGY</classCode><classCode scheme="WOS">GENETICS & HEREDITY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:5285C50C5E85B65CB52977E9337CFD2862CC522E
|texte= Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
}}
| This area was generated with Dilib version V0.6.23. |  |